RE:RE:RE:RE:RE:RE:7% "He has over ten millin to pick over the bones of what??"
CZO has $11 million cash, no debt, and $5.14 million in inventory on standby for a business with >50% margins. He has the cash to get to key strategic milestones like PGX scale-up and a partnership deal providing important validation for PGX. CZO has said it is in talks with serious comapnies that understand the importance of bioavailability. Gilles said CoQ10 is a $4 billion market. CZO also has other pipeline assets before key milestones. Avalyn raised $80 million going into its Phase I and used the same Dr. Kolb as CZO is using. Dr. Kolb is a leader in the field of fibrosis and has said that if CZO's results are replicated in humans it could profoundly change the treatment landscape. The avenanthramide trial is also expected to begin recruiting in the next 1 1/2 months. Lots happening in CZO and much of it is still secret. CZO has the cash such that it isn't dependent on telling the world about what it has before it is ready. These next catalysts will be key and a coming out party potentially on NASDAQ.